| 前收市價 | 5.20 |
| 開市 | 7.10 |
| 買盤 | 6.50 |
| 賣出價 | 7.80 |
| 拍板 | 37.50 |
| 到期日 | 2024-10-18 |
| 今日波幅 | 7.10 - 7.10 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 14 |
ZacksIonis (IONS) Expands Licensing Deal With Otsuka for HAE Drug
Ionis (IONS) out-licenses the rights for its HAE drug to Otsuka in the Asia-Pacific region. The companies signed a similar deal last year granting Otsuka rights to market the drug in Europe.
ZacksIonis Pharmaceuticals (IONS) Down 0.7% Since Last Earnings Report: Can It Rebound?
Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BenzingaEurope Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
On Thursday, the European Commission granted marketing authorization under exceptional circumstances and maintained orphan designation for Biogen Inc’s (NASDAQ:BIIB) Qalsody (tofersen) for amyotrophic lateral sclerosis (ALS) associated with a mutation in the superoxide dismutase 1 gene (SOD1-ALS). Qalsody is the first treatment approved in the European Union to target a genetic cause of ALS, also known as motor neuron disease (MND). SOD1-ALS is an ultra-rare genetic form of ALS estimated to affe
